

September 19, 2014

ContraFect

MOLECULAR TREATMENTS
FOR INFECTIOUS DISEASE



ContraFect Corporation to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference

YONKERS, NEW YORK -- (Marketwired) -- 09/19/14 -- [**ContraFect Corporation**](#) (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer and Barry Kappel, the Company's senior vice president of business development, will present a corporate overview at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY on Friday, September 26 at 8:30 AM EST. Ms. Gregory and Dr. Kappel will discuss ContraFect's lead programs, CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections and CF-404, a universal treatment for life-threatening influenza infections.

The presentation will be available as a webcast for a limited time. To access via the Company's website, please go to www.contrafect.com. To access the webcast directly, please use the following URL: <https://www.webcaster4.com/Webcast/Page/392/5771>.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

About BioCentury NewsMakers in the Biotech Industry Conference:

NewsMakers presents a hand-picked group of public biotech companies whose corporate and regulatory milestones will drive stock prices. NewsMakers is recognized as the industry's key venue for companies to take their story to Wall Street each Fall. Thus,

NewsMakers remains the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

Barry Kappel, Ph.D., MBA
SVP Business Development
Tel: 914-207-2300
E-Mail: [Email Contact](#)
or visit: www.contrafect.com

Source: ContraFect Corporation